Our findings support further exploration into the clinical application of NAT10 inhibitors or DKK2-neutralizing antibodies as adjuvants for PD-1 blockade, particularly in ICB-refractory CRC subsets. This evidence concerns the gene DKK2 and colorectal carcinoma.